Neovacs S.A.

RSS Feed
Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohn's disease, Rheumatoid Arthritis and lupus disease. Neovacs SA's portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
  • TickerA1CVKR
  • ISINFR0004032746
  • ExchangeFrankfurt Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

GlobeNewsWire

Neovacs announces the full results of its Phase IIb Clinical study of IFNalpha Kinoid in lupus - 13th International Lupus Congress 2019

Neovacs announces the full results of its Phase IIb Clinical study of IFNalpha Kinoid in lupus - 13th International Lupus Congress 2019 PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THE FULL RESULTS OF ITSPHASE IIb CLINICAL STUDY OF IFNα KINOID IN LUPUS, PRESENTED AT THE 13th INTERNATIONAL LUPUS CONGRESS 2019 Paris and Boston, April 9, 2019, 7:30 am CEST – NEOVACS (Euronext Growth Paris: ALNEV) leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases, announced that the full results of the phase IIb clinical study were presented...

Free
Press Releases
Health Care
Neovacs S.A.
9d 09/04/2019 EN
GlobeNewsWire

2019 Financial Calendar

2019 Financial Calendar PRESS RELEASE PRESS RELEASE PRESS RELEASE 2019 Financial Calendar Paris, April 5, 2019, 5:45 pm CEST – NEOVACS (Euronext Growth Paris: ALNEV) leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases publishes an updated 2019 financial calendar today. Financial announcements will be published before the market opening. The expected dates are preliminary so may be subject to change. 2018 Annual Results                                                                     March 25, 2019Annual General...

Free
Press Releases
Health Care
Neovacs S.A.
13d 05/04/2019 EN
GlobeNewsWire

Neovacs announces an agreement with Biosyn GmbH to diversify its supply of Keyhole Limpet Hemocyanin (KLH)

Neovacs announces an agreement with Biosyn GmbH to diversify its supply of Keyhole Limpet Hemocyanin (KLH) PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES AN AGREEMENT WITH BIOSYN GmbH        TO DIVERSIFY ITS SUPPLY OF KEYHOLE LIMPET HEMOCYANIN (KLH)   Paris et Boston, april 1st 2019 - 07h30 CEST - Neovacs (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto-immune diseases, today announces that the company has signed a new supply agreement with the German company biosyn GmbH to diversify its sourcing of KLH, one of the three co...

Free
Press Releases
Health Care
Neovacs S.A.
17d 01/04/2019 EN
GlobeNewsWire

Neovacs reports full-year 2018 Financial results and provides corporate update

Neovacs reports full-year 2018 Financial results and provides corporate update RESS RELEASE ·  PRESS RELEASE  · PRESS RELEASE NEOVACS REPORTS FULL-YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE KEY OPINION LEADERS VALIDATE THE THERAPEUTIC POTENTIAL OF IFNα KINOID IN  LUPUS TREATMENT FOLLOWING THE RESULTS OF THE PHASE IIB CLINICAL STUDY  SUCCESSFUL IN VIVO PROOF OF CONCEPT  FOR ITS IL-4 / IL-13 KINOID A NEW THERAPEUTIC VACCINE  TO TREAT MITE-INDUCED ASTHMA PATENT REGISTERED IN EUROPE AND THE U.S. FOR IL-4 / IL-13 KINOID, CANDIDATE   VACCINE IN THE TREATMENT OF ALLERGIES FINANCI...

Free
Press Releases
Health Care
Neovacs S.A.
24d 25/03/2019 EN
GlobeNewsWire

Neovacs announces two appointments to its executive committee

Neovacs announces two appointments to its executive committee PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES TWO APPOINTMENTS TO ITS EXECUTIVE COMMITTEE Vincent Serra, PhD – Chief Scientific OfficerValerie Salentey, Pharm D - Head of Regulatory Affairs Paris & Boston, February 20th, 2019 - 07h30 CET - Neovacs (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases announces two appointments to its Executive Committee. Vincent Serra, PhD is appointed Chief Scientific Officer. Wit...

Free
Press Releases
Health Care
Neovacs S.A.
57d 20/02/2019 EN
Invest Securities
Martial Descoutures ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - Neovacs : Des questions en suspens - SOUS REVUE vs ACHAT, SOUS REVUE vs 1€

La biotech française vient d'annoncer ses résultats de phase IIb évaluant son IFNα Kinoïde dans le traitement du lupus. Alors que la signature interféron (efficacité biologique de la molécule) ainsi que deux scores tests ressortent positivement (statistiquement significatif pour l'IFN signature et LLDAS, soit bonne tendance avec SRI4), nous restons circonspects sur le manque d'efficacité observée par le score BICLA. L'histoire de NEOVACS est dorénavant entièrement tournée vers un partenariat. Suite à cette publication, nous mettons notre recommandation et objectif sous revue. Conférence téléph...

Equity
Health Care
Neovacs S.A.
289d 03/07/2018 4 FR
GBC AG
Cosmin Filker

Neovacs S.A. - Research Comment - 21.06.18

Neovacs ist ein Biotechnologieunternehmen, das sich auf eine kinoide Technologieplattform zur aktiven Immuntherapie im Bereich Autoimmun- und/oder Entzündungskrankheiten spezialisiert hat. Auf Basis der unternehmenseigenen Technologie zur Einleitung einer poliklonalen Immunantwort (welche durch sechs Patentfamilien bis mindestens 2023 geschützt ist) konzentriert Neovacs seine Entwicklungsaktivitäten auf die aktive Immuntherapie IFNα-Kinoid, welche für die Indikationen SLE (Systemischer Lupus Erythematodes) und DM (Dermatomyositis) untersucht wird. Neovacs führt außerdem präklinische Studien zu...

EUR 160.00
Equity
Health Care
Neovacs S.A.
301d 21/06/2018 5 DE
Invest Securities
Martial Descoutures ...
  • Thibaut Voglimacci-Stephanopoli

L'année de tous les enjeux (ACHAT ; OC : 1,1€)

La biotech française publiera dans 6 mois ses résultats cliniques de son IFNα Kinoïde dans le Lupus. Ses résultats seront déterminants pour l'histoire de la société, car s'ils s'avéraient positifs, ils pourraient permettre d'enregistrer le produit dès cette phase IIb en Corée. La consolidation financière réalisée par l'intermédiaire de deux opérations de refinancements l'année dernière permet de se focaliser essentiellement sur la clinique cette année, avec des résultats complémentaires de POC dans le Diabète de type 1 et l'accélération d'inclusion de la phase IIa en Dermatomyosite (n=30). Nou...

Equity
Health Care
Neovacs S.A.
1y 29/01/2018 21 FR
GBC AG
Cosmin Filker

GESCHÄFTSENTWICKLUNG 1.HJ 2017

Die Neovacs S.A. ist ein Biotechnologieunternehmen, das sich auf eine Technologieplattform, genannt„Kinoid“, zur aktiven Immuntherapie im Bereich Autoimmun- und Entzündungskrankheiten spezialisiert hat.Auf Basis der unternehmenseigenen Technologie zur Einleitung einer poliklonalen Immunantwort (welchedurch sechs Patentfamilien bis mindestens 2032 geschützt ist) konzentriert Neovacs seine Entwicklungsaktivitäten auf die aktive Immuntherapie mit IFNα-Kinoid, welche für die Indikationen SLE (Systemischer Lupus Erythematodes) und DM (Dermatomyositis) untersucht wird. Neovacs führt außerdem präklin...

EUR 163.60
Equity
Health Care
Neovacs S.A.
1y 19/12/2017 8 DE
Invest Securities
Martial Descoutures ...
  • Thibaut Voglimacci

Un placement en amont d'une période charnière - ACHAT - OC 1,3€ (vs 1,65€)

Suite au placement privé de 6m€ réalisé au mois d’août, nous ajustons notre objectif de cours à 1,30€ vs 1,65€ préc. Ce placement bien que dilutif permet d’améliorer la visibilité financière durant ces prochains mois capitaux pour la société et lui permet de se consacrer essentiellement à la clinique: conclusion de la phase IIb de son IFNalpha Kinoide dans le Lupus, résultats de la phase IIa en dermatomyosite et résultats de preuve de concept dans le diabète de type 1. En amont de ces résultats cliniques, et au vu de la valorisation actuelle de la société, nous maintenons notre recommandation ...

Equity
Health Care
Neovacs S.A.
1y 29/08/2017 4 FR
GlobeNewsWire

Neovacs announces the full results of its Phase IIb Clinical study of IFNalpha Kinoid in lupus - 13th International Lupus Congress 2019

Neovacs announces the full results of its Phase IIb Clinical study of IFNalpha Kinoid in lupus - 13th International Lupus Congress 2019 PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THE FULL RESULTS OF ITSPHASE IIb CLINICAL STUDY OF IFNα KINOID IN LUPUS, PRESENTED AT THE 13th INTERNATIONAL LUPUS CONGRESS 2019 Paris and Boston, April 9, 2019, 7:30 am CEST – NEOVACS (Euronext Growth Paris: ALNEV) leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases, announced that the full results of the phase IIb clinical study were presented...

Free
Press Releases
Health Care
Neovacs S.A.
9d 09/04/2019 EN
GlobeNewsWire

2019 Financial Calendar

2019 Financial Calendar PRESS RELEASE PRESS RELEASE PRESS RELEASE 2019 Financial Calendar Paris, April 5, 2019, 5:45 pm CEST – NEOVACS (Euronext Growth Paris: ALNEV) leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases publishes an updated 2019 financial calendar today. Financial announcements will be published before the market opening. The expected dates are preliminary so may be subject to change. 2018 Annual Results                                                                     March 25, 2019Annual General...

Free
Press Releases
Health Care
Neovacs S.A.
13d 05/04/2019 EN
GlobeNewsWire

Neovacs announces an agreement with Biosyn GmbH to diversify its supply of Keyhole Limpet Hemocyanin (KLH)

Neovacs announces an agreement with Biosyn GmbH to diversify its supply of Keyhole Limpet Hemocyanin (KLH) PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES AN AGREEMENT WITH BIOSYN GmbH        TO DIVERSIFY ITS SUPPLY OF KEYHOLE LIMPET HEMOCYANIN (KLH)   Paris et Boston, april 1st 2019 - 07h30 CEST - Neovacs (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto-immune diseases, today announces that the company has signed a new supply agreement with the German company biosyn GmbH to diversify its sourcing of KLH, one of the three co...

Free
Press Releases
Health Care
Neovacs S.A.
17d 01/04/2019 EN
GlobeNewsWire

Neovacs reports full-year 2018 Financial results and provides corporate update

Neovacs reports full-year 2018 Financial results and provides corporate update RESS RELEASE ·  PRESS RELEASE  · PRESS RELEASE NEOVACS REPORTS FULL-YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE KEY OPINION LEADERS VALIDATE THE THERAPEUTIC POTENTIAL OF IFNα KINOID IN  LUPUS TREATMENT FOLLOWING THE RESULTS OF THE PHASE IIB CLINICAL STUDY  SUCCESSFUL IN VIVO PROOF OF CONCEPT  FOR ITS IL-4 / IL-13 KINOID A NEW THERAPEUTIC VACCINE  TO TREAT MITE-INDUCED ASTHMA PATENT REGISTERED IN EUROPE AND THE U.S. FOR IL-4 / IL-13 KINOID, CANDIDATE   VACCINE IN THE TREATMENT OF ALLERGIES FINANCI...

Free
Press Releases
Health Care
Neovacs S.A.
24d 25/03/2019 EN
GlobeNewsWire

Neovacs announces two appointments to its executive committee

Neovacs announces two appointments to its executive committee PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES TWO APPOINTMENTS TO ITS EXECUTIVE COMMITTEE Vincent Serra, PhD – Chief Scientific OfficerValerie Salentey, Pharm D - Head of Regulatory Affairs Paris & Boston, February 20th, 2019 - 07h30 CET - Neovacs (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases announces two appointments to its Executive Committee. Vincent Serra, PhD is appointed Chief Scientific Officer. Wit...

Free
Press Releases
Health Care
Neovacs S.A.
57d 20/02/2019 EN
Ford Equity Research

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

EUR 18.47
Quantitative
Health Care
Neovacs S.A.
2y 16/12/2016 2 EN
Proxinvest

Proxy Report - 09/03/2018

La société ne justifie pas les nombreuses demandes d'autorisation d'augmentation de capital proposées lors de cette assemblée générale mixte alors qu'elle avait déjà demandé de nombreuses autorisations de ce type lors de la précédente assemblée générale tenue en mai 2017 et qui ont donc été utilisées (il convient de noter que les résultats de vote n'ont pas été publiés). La presque totalité des autorisations demandées portent sur un montant identique représentant 100% du capital, ce qui est bien trop élevé pour être accepté. En effet, les actionnaires préfèreraient la convocation d'une assemb...

EUR 508.93
SRI
Health Care
Neovacs S.A.
1y 22/02/2018 14 FR

ResearchPool Subscriptions

Get the most out of your insights

Get in touch